Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2001 September; 85(5): 683–686.
PMCID: PMC2364134

Non-melanoma skin cancers and glucocorticoid therapy


Non-melanoma skin cancer (NMSC) is an important cause of morbidity and long-term mortality in organ transplant recipients receiving immunosuppressive drugs such as azathioprine and cyclosporin, often combined with adrenocortical steroids (glucocorticoids). At lower doses, glucocorticoids alone are prescribed for other conditions including musculoskeletal, connective tissue and respiratory disorders. Presently, it is unknown whether patients taking glucocorticoids are at an increased risk of skin malignances. In a population-based case-control study in New Hampshire, USA, we compared use of glucocorticoids in 592 basal cell carcinoma (BCC) and 281 squamous cell carcinoma (SCC) cases and in 532 age and gender matched controls; neither cases nor controls had a history of organ transplantation. Participants underwent a structured personal interview regarding history of medication use and skin cancer risk factors. We used unconditional logistic regression analysis to compute odds ratios associated with glucocorticoid use for 1 month or longer while controlling for potential confounding factors. Risk of SCC was increased among users of oral glucocorticoids (adjusted odds ratio = 2.31; 95% CI = 1.27, 4.18), and risk of BCC was elevated modestly (adjusted odds ratio = 1.49; 95% CI = 0.90, 2.47). In contrast, risk of both SCC and BCC were unrelated to use of inhaled steroids. Our data suggest that use of oral glucocorticoids may increase risk of NMSC, and SCC in particular, among patients other than organ transplant recipients. We hypothesize that immunosuppression induced by oral glucocorticoids may allow these cancers to emerge from immunosurveillance. © 2001 Cancer Research Campaign

Keywords: non-melanoma skin cancer, squamous cell carcinoma, basal cell carcinoma, glucocorticoids, immunosuppressive therapy, case-control study

Full Text

The Full Text of this article is available as a PDF (46K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Blohmé I, Larkö O. Premalignant and malignant skin lesions in renal transplant patients. Transplantation. 1984 Feb;37(2):165–167. [PubMed]
  • Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A, O'Sullivan B, Siskind V, Van Der Woude FJ, Hardie IR. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation. 1996 Mar 15;61(5):715–721. [PubMed]
  • Coebergh JW, Neumann HA, Vrints LW, van der Heijden L, Meijer WJ, Verhagen-Teulings MT. Trends in the incidence of non-melanoma skin cancer in the SE Netherlands 1975-1988: a registry-based study. Br J Dermatol. 1991 Oct;125(4):353–359. [PubMed]
  • Dyall-Smith D, Ross JB. Cutaneous malignancies in renal transplant recipients from Nova Scotia, Canada. Australas J Dermatol. 1995 May;36(2):79–82. [PubMed]
  • Gallagher RP, Ma B, McLean DI, Yang CP, Ho V, Carruthers JA, Warshawski LM. Trends in basal cell carcinoma, squamous cell carcinoma, and melanoma of the skin from 1973 through 1987. J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):413–421. [PubMed]
  • Gupta AK, Cardella CJ, Haberman HF. Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol. 1986 Nov;122(11):1288–1293. [PubMed]
  • Hoxtell EO, Mandel JS, Murray SS, Schuman LM, Goltz RW. Incidence of skin carcinoma after renal transplantation. Arch Dermatol. 1977 Apr;113(4):436–438. [PubMed]
  • Jensen P, Hansen S, Møller B, Leivestad T, Pfeffer P, Geiran O, Fauchald P, Simonsen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):177–186. [PubMed]
  • Kaldor J, Shugg D, Young B, Dwyer T, Wang YG. Non-melanoma skin cancer: ten years of cancer-registry-based surveillance. Int J Cancer. 1993 Apr 1;53(6):886–891. [PubMed]
  • Karagas MR, Greenberg ER, Spencer SK, Stukel TA, Mott LA. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer. 1999 May 17;81(4):555–559. [PubMed]
  • Kripke ML. Ultraviolet radiation and immunology: something new under the sun--presidential address. Cancer Res. 1994 Dec 1;54(23):6102–6105. [PubMed]
  • Levi F, Franceschi S, Te VC, Randimbison L, La Vecchia C. Trends of skin cancer in the Canton of Vaud, 1976-92. Br J Cancer. 1995 Oct;72(4):1047–1053. [PMC free article] [PubMed]
  • McCann J. Can skin cancers be minimized or prevented in organ transplant patients? J Natl Cancer Inst. 1999 Jun 2;91(11):911–913. [PubMed]
  • O'Connell BM, Abel EA, Nickoloff BJ, Bell BJ, Hunt SA, Theodore J, Shumway NE, Jacobs PH. Dermatologic complications following heart transplantation. J Heart Transplant. 1986 Nov-Dec;5(6):430–436. [PubMed]
  • Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, Medsger TA, Jr, Kwoh CK. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum. 1995 Aug;38(8):1120–1127. [PubMed]
  • Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, Emre S, Fishbein TM, Guy SR, Schwartz ME, et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation. 2000 Mar 15;69(5):781–789. [PubMed]
  • Staples M, Marks R, Giles G. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect? Int J Cancer. 1998 Oct 5;78(2):144–148. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK